Tag Archives: Dr Daniel Speidel

Evotec-Backed Breakpoint Therapeutics Nominates Breakthrough Cancer Treatment Candidate BTX-011 for Clinical Development

(IN BRIEF) Breakpoint Therapeutics GmbH, a company focused on developing drugs targeting the DNA Damage Response (DDR), has nominated its first preclinical development candidate, BTX-011, an inhibitor of polymerase theta (Pol θ / POLQ), for the treatment of solid tumors. … Read the full press release